Immune response profiles triggered by SARS-CoV-2 infection or vaccines are notably different

Posted on Jul 15, 2021

Infection with SARS-CoV-2 initiates a myriad of innate and adaptive immune responses that while largely heterogeneous, have been shown to correlate with disease severity, progression and the development of long lasting immunity. In most individuals, these multiple immunological memory mechanisms against SASR-CoV-2 are retained for at least 8 months, explaining the low reinfection rates observed in most populations (1-10%).

Indeed, recent studies indicate previous infection provides an estimated 80-95% protection from reinfection in people under 65 years old for at least 6 months. With global estimated confirmed COVID-19 cases in excess of 180 million and more than 170 million people recovered, it would be expected that 136 million people worldwide have developed some degree of immunity to COVID-19 from a previous SARS-CoV-2 infection.

Detailed investigations of immune responses have revealed notable differences in immune mechanisms triggered by SARS-CoV-2 infection with increasing disease severity, and in response to COVID-19 mRNA vaccines.

To further discuss Airfinity's COVID-19 vaccine and therapeutics platforms, get in touch with the team.

More Insights From Airfinity

Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases

Oct 10, 2022

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

Aug 25, 2022

Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir

Jul 25, 2022

COVID-19 vaccines sales to bounce back with new jabs taking a fifth of the 2022 market

Jul 15, 2022

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Jul 13, 2022

Global wastage of COVID-19 vaccines could be 1.1 billion doses

Jul 11, 2022